SCHEMBL4289150

SCHEMBL4289150

COc1ccc(CNc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 20/20 1.00
HIPK2 Q9H2X6 6/20 0.69
CDK2 P24941 6/20 0.69
DAPK3 O43293 6/20 0.69
CDK5 Q00535 6/20 0.69
DYRK1A Q13627 6/20 0.69
PAK4 O96013 5/20 0.69
CLK2 P49760 5/20 0.69
PRKX P51817 5/20 0.69
MELK Q14680 5/20 0.69
CDK7 P50613 4/20 0.69
CAMK2D Q13557 4/20 0.69
STK17A Q9UEE5 4/20 0.69
GSK3B P49841 4/20 0.69
FLT3 P36888 3/20 0.69
GSK3A P49840 3/20 0.69
CLK4 Q9HAZ1 3/20 0.69
CDK8 P49336 2/20 0.69
JAK2 O60674 5/20 0.67
ROCK2 O75116 5/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4286354 0.92 CDC7 (1.00) CDC7HIPK2CDK2DAPK3CDK5
SCHEMBL4293420 0.90 CDC7 (1.00) CDC7HIPK2CDK2DAPK3CDK5
SCHEMBL4297753 0.86 CDC7 (1.00) CDC7HIPK2CDK2DAPK3CDK5
SCHEMBL4289509 0.84 CDC7 (1.00) CDC7HIPK2CDK2DAPK3CDK5
SCHEMBL4300135 0.83 CDC7 (1.00) CDC7HIPK2CDK2DAPK3CDK5
SCHEMBL3670659 0.81 CDC7 (1.00) CDC7HIPK2CDK2DAPK3CDK5
SCHEMBL4292579 0.81 CDC7 (1.00) CDC7HIPK2CDK2DAPK3CDK5
SCHEMBL3666862 0.81 CDC7 (1.00) CDC7HIPK2CDK2DAPK3CDK5
SCHEMBL3666765 0.80 CDC7 (0.81) CDC7HIPK2CDK2DAPK3CDK5
SCHEMBL3666682 0.79 CDC7 (1.00) CDC7HIPK2CDK2DAPK3CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885HIPK2 256/4885CDK2 65/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885HIPK2 256/4885CDK2 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.